Symptoms and General Pathology

All Conditions

Gland and Hormone Related Diseases

Neoplasms

Nervous System Diseases

Rare Diseases

Syndrome

Cushing Syndrome

ACTH-Secreting Pituitary Adenoma

Pituitary ACTH Hypersecretion

Adenoma

Pituitary Diseases

Adrenocortical Hyperfunction

Adrenal Gland Diseases

Endocrine System Diseases

Hypothalamic Diseases

Brain Diseases

Central Nervous System Diseases

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Pituitary Neoplasms

Endocrine Gland Neoplasms

Cushing's Syndrome

ACTH-secreting Pituitary Adenoma

Hyperadrenalism

Anti-Infective Agents

All Drugs and Chemicals

Ketoconazole

Levoketoconazole taken twice daily up to 1200 mg daily

Levoketoconazole

Fredric Cohen, MD

This is a long-term, open-label extension study of levoketoconazole in subjects with endogenous Cushing's Syndrome.

This is a long-term, OLE study of levoketoconazole in subjects with endogenous CS who have completed one or both parent studies or otherwise potentially qualify for this study, as defined in the eligibility criteria.

Open-label Treatment in Cushing's Syndrome

An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Changes or shifts from baseline in late night salivary cortisol levels

Changes from Baseline in the incidence and severity of AEs, SAEs, AESIs

Cortendo AB

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Open-label Treatment in Cushing's Syndrome	NCT03621280	Cushing Syndrom... Cushing Disease	Levoketoconazol...	18 Years -	Cortendo AB
Open-label Treatment in Cushing's Syndrome	NCT03621280	Cushing Syndrom... Cushing Disease	Levoketoconazol...	18 Years -	Cortendo AB

Spots Global Cancer Trial Database for levoketoconazole